When someone gets a flu vaccine, they are primarily protecting themselves — but they also reduce the probability that they'll infect their coworkers, family members, and strangers on public transit. Those third-party beneficiaries receive the benefit of reduced infection risk for free. The vaccinated person paid for their own protection but not the protection conferred on others. This gap — between the private benefit the individual captured and the social benefit the vaccination created — is a positive externality. And because individuals only respond to their private benefit when deciding whether to vaccinate, vaccination rates fall below what is socially optimal.
In plain terms
A positive externality exists when a market transaction creates benefits for third parties who did not pay for them. The buyer receives the private benefit and pays the market price; third parties receive a spillover benefit for free. Because the market price only reflects private benefit, goods with positive externalities are underpriced and underproduced.
The result is the mirror image of negative externalities:
Social MB = Private MB + External Benefit
Because social MB > private MB, the efficient quantity is larger than the market quantity. The market stops producing at the point where private MB = private MC — but society would benefit from more production (where social MB = social MC). The gap represents underproduction and forgone social value.
The HHS immunization research documents the magnitude of vaccination externalities: each percentage point increase in flu vaccination coverage reduces transmission rates non-linearly — the benefit extends far beyond the vaccinated individuals to the broader population through herd immunity.
Why it works this way
Positive externalities arise whenever knowledge, health, capability, or infrastructure improvements spill over beyond the direct transaction. The social value of a research discovery — flowing through imitation, applications in adjacent industries, and cumulative technological progress — routinely exceeds the private value captured by the discovering firm. This is the economic foundation for R&D tax credits: the IRS R&D Tax Credit subsidizes private research investment to bring it closer to the socially efficient level.
A real example
Education is the most widely cited positive externality in economics. An educated worker is more productive — a private benefit captured in their wages. But education also creates external benefits: more capable citizens make better political decisions, higher educational attainment in a community raises productivity of coworkers and local businesses, and human capital spillovers accelerate innovation. The Census Bureau's data on educational attainment and community outcomes documents correlations between educational attainment and lower crime rates, better public health outcomes, and higher civic participation — the external benefits that justify public education subsidies beyond the private returns.
Why it matters
Positive externalities justify subsidies, public provision, and mandates — the three main policy tools for correcting underproduction. Education is publicly funded; vaccination is subsidized and incentivized; basic research is funded by the government at levels that private markets would not sustain. The question is always: how large is the external benefit, and does the subsidy bring production close enough to the efficient level to justify its cost? This cost-benefit question is at the center of debates about education spending, healthcare coverage mandates, and public investment in basic science.
